Evaluate onset of effect in patients with Chronic Obstructive Pulmonary Disease (COPD) treated with formoterol Turbuhaler®

Study identifier:D5127C00001

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A randomised, placebo-controlled, double-blind (double-dummy technique),crossover, multi-centre study, to evaluate onset of effect in patients with Chronic Obstructive Pulmonary Disease (COPD) treated with formoterol Turbuhaler® 9 μg, compared with Serevent® Diskus® 50 μg.

Medical condition

Chronic Obstructive Pulmonary Disease

Phase

Phase 2

Healthy volunteers

No

Study drug

Formoterol, Formoterol, Formoterol, Formoterol, Formoterol, Formoterol, Salmeterol, Salmeterol, Salmeterol, Salmeterol, Salmeterol, Salmeterol, Placebo, Placebo, Placebo, Placebo, Placebo, Placebo

Sex

All

Actual enrollment

109

Study type

Interventional

Age

40 Years +

Date

Study Start Date: 01 Jan 2010
Primary Completion Date: 01 May 2010
Study Completion Date: 01 May 2010

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2012 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria